Home
>
National Drug Code (NDC)
>
Chlordiazepoxide Hydrochloride and Clidinium Bromide
Chlordiazepoxide Hydrochloride and Clidinium Bromide - 42291-213-90 - (CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE)
Drug Information of Chlordiazepoxide Hydrochloride and Clidinium Bromide
| Product NDC: | 42291-213 |
| Proprietary Name: | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
| Non Proprietary Name: | CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE |
| Active Ingredient(s): | 5; 2.5 mg/1; mg/1 & nbsp; CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Chlordiazepoxide Hydrochloride and Clidinium Bromide
| Product NDC: | 42291-213 |
| Labeler Name: | AvKARE, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | |
| Marketing Category: | UNAPPROVED DRUG OTHER |
| Start Marketing Date: | 20130103 |
Package Information of Chlordiazepoxide Hydrochloride and Clidinium Bromide
| Package NDC: | 42291-213-90 |
| Package Description: | 90 CAPSULE in 1 BOTTLE (42291-213-90) |
NDC Information of Chlordiazepoxide Hydrochloride and Clidinium Bromide
| NDC Code | 42291-213-90 |
| Proprietary Name | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
| Package Description | 90 CAPSULE in 1 BOTTLE (42291-213-90) |
| Product NDC | 42291-213 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 20130103 |
| Marketing Category Name | UNAPPROVED DRUG OTHER |
| Labeler Name | AvKARE, Inc. |
| Substance Name | CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE |
| Strength Number | 5; 2.5 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Benzodiazepine [EPC],Benzodiazepines [Chemical/Ingredient],Anticholinergic [EPC],Decreased Parasympathetic Acetylcholine Activity [PE],GI Motility Alteration [PE],Digestive/GI System Activity Alteration [PE],Cholinergic Antagonists [MoA] |
